Inhaled corticosteroids in COPD
123 results
1 - 100
Inhaled corticosteroids in COPD 
Inhaled corticosteroids increase pneumonia risk in stable COPD- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review- Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
- Inhaled steroids only decrease COPD exacerbations slightly
- Corticosteroids benefit patients with moderate to severe COPD
- Steroid inhalers increase fracture risk in COPD
- Inhaled corticosteroids and risk of fractures
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
- Triple inhaled therapy for COPD effective for selected patients
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Inhaled budesonide for COPD not associated with pneumonia
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease: Cochrane systematic review
- Antibiotic and corticosteroid treatment effective for acute exacerbations of COPD
- Chronic obstructive pulmonary disease (COPD)
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
- Low-dose theophylline is minimally helpful, if at all, in preventing COPD exacerbations
- Salmeterol + fluticasone better than tiotropium in COPD (INSPIRE)
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis
- Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
- Oral corticosteroids for stable chronic obstructive pulmonary disease
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
- Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
- LABA+LAMA+ICS associated with greater decline in all-cause mortality than LABA+LAMA in patients with severe COPD (IMPACT)
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
- Tiotropium via Soft Mist Inhaler increases all-cause mortality in COPD
- Long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Inhaled corticosteroids for bronchiectasis: Cochrane systematic review
- USPSTF 2022: Recommendation against screening for chronic obstructive pulmonary disease (D recommendation)
- Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
- Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Triple inhaled therapy provides a small reduction in moderate exacerbations, no effect on severe exacerbations (ETHOS)
- Guidelines for the management of COPD
- Inhaled short‐acting beta2‐agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
- Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)